Symbols / GNLX Stock $2.92 -1.52% Genelux Corporation

Healthcare • Biotechnology • United States • NCM
GNLX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Thomas D. Zindrick J.D.
Exch · Country NCM · United States
Market Cap 130.93M
Enterprise Value 107.95M
Income -33.58M
Sales 8.00K
FCF (ttm) -15.33M
Book/sh 0.52
Cash/sh 0.59
Employees 25
Insider 10d —
IPO Jan 26, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.83
PEG —
P/S 16,366.75
P/B 5.66
P/C —
EV/EBITDA -3.14
EV/Sales 13,494.12
Quick Ratio 3.60
Current Ratio 3.68
Debt/Eq 10.88
LT Debt/Eq —
EPS (ttm) -0.85
EPS next Y -0.76
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -60.56%
ROE -127.28%
ROIC —
Gross Margin 100.00%
Oper. Margin -4,321.12%
Profit Margin 0.00%
Shs Outstand 44.84M
Shs Float 36.20M
Insider Own 10.70%
Instit Own 30.68%
Short Float 7.21%
Short Ratio 18.71
Short Interest 3.14M
52W High 8.54
vs 52W High -65.79%
52W Low 2.29
vs 52W Low 27.51%
Beta 0.55
Impl. Vol. 5.46%
Rel Volume 1.27
Avg Volume 190.75K
Volume 241.80K
Target (mean) $17.50
Tgt Median $16.00
Tgt Low $10.00
Tgt High $31.00
# Analysts 6
Recom None
Prev Close $2.96
Price $2.92
Change -1.52%
About

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$17.50
Mean price target
2. Current target
$2.92
Latest analyst target
3. DCF / Fair value
$-6.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.92
Low
$10.00
High
$31.00
Mean
$17.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-20 main Benchmark Speculative Buy → Speculative Buy $20
2025-10-21 init Lake Street — → Buy $16
2025-07-21 init LUCID CAPITAL MARKETS — → Buy $10
2025-05-08 main Benchmark Speculative Buy → Speculative Buy $23
2025-03-31 reit HC Wainwright & Co. Buy → Buy $30
2025-03-25 reit HC Wainwright & Co. Buy → Buy $30
2024-11-15 main HC Wainwright & Co. Buy → Buy $30
2024-10-29 init Guggenheim — → Buy $8
2024-08-27 init Roth MKM — → Buy $10
2024-08-15 reit HC Wainwright & Co. Buy → Buy $32
2024-06-03 reit Benchmark Speculative Buy → Speculative Buy $25
2024-05-31 main Benchmark Speculative Buy → Speculative Buy $25
2024-05-13 reit HC Wainwright & Co. Buy → Buy $32
2024-04-03 reit Benchmark Speculative Buy → Speculative Buy $30
2024-04-02 main HC Wainwright & Co. Buy → Buy $32
2023-11-27 init HC Wainwright & Co. — → Buy $35
2023-11-24 main Benchmark Speculative Buy → Speculative Buy $30
2023-09-12 init Maxim Group — → Buy $40
2023-06-09 main Benchmark Speculative Buy → Speculative Buy $38
2023-05-18 init Brookline Capital — → Hold $25
News
RSS: Latest GNLX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-16 CAPPELLO JOSEPH Chief Technology Officer — 174,841 $0.00 $0
2026-06-16 SMITHER JOHN W Director — 28,409 $0.00 $0
2026-06-16 TYREE JAMES L Director — 28,409 $0.00 $0
2026-06-16 GROEN ERIC General Counsel — 233,957 $0.00 $0
2026-06-16 ZINDRICK THOMAS Chief Executive Officer — 730,601 $0.00 $0
2026-06-16 YU YONG Officer — 119,318 $0.00 $0
2026-06-16 MIRABELLI MARY Director — 28,409 $0.00 $0
2026-06-16 THOMAS JOHN Director — 28,409 $0.00 $0
2026-06-03 SMALLING RALPH Officer — 192 $2.93 $563
2026-06-01 THOMAS JOHN Director — 10,000 $2.98 $29,801
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.01
+0.00%
0.01
-95.29%
0.17
-98.46%
11.07
Operating Revenue
0.01
+0.00%
0.01
-95.29%
0.17
-98.46%
11.07
Operating Expense
33.22
+4.79%
31.70
+30.28%
24.34
+72.82%
14.08
Research And Development
19.85
+4.49%
19.00
+48.81%
12.77
+40.64%
9.08
Selling General And Administration
13.37
+5.23%
12.71
+9.84%
11.57
+131.22%
5.00
General And Administrative Expense
13.37
+5.23%
12.71
+9.84%
11.57
+131.22%
5.00
Salaries And Wages
8.49
+9.87%
7.73
+14.13%
6.77
+89.85%
3.57
Other Gand A
4.01
-0.05%
4.01
+7.88%
3.72
+237.39%
1.10
Total Expenses
33.22
+4.79%
31.70
+30.28%
24.34
+72.82%
14.08
Operating Income
-33.21
-4.79%
-31.70
-31.16%
-24.16
-702.02%
-3.01
Total Operating Income As Reported
-33.21
-4.79%
-31.70
-31.16%
-24.16
-702.02%
-3.01
EBITDA
-32.64
-6.00%
-30.79
-16.39%
-26.46
-1428.42%
-1.73
Normalized EBITDA
-32.64
-4.74%
-31.16
-19.60%
-26.05
-1174.08%
-2.04
Reconciled Depreciation
0.57
-36.43%
0.90
-11.30%
1.02
+5.17%
0.97
EBIT
-33.21
-4.79%
-31.70
-15.36%
-27.48
-917.97%
-2.70
Total Unusual Items
0.00
-100.00%
0.37
+192.04%
-0.40
-228.03%
0.31
Total Unusual Items Excluding Goodwill
0.00
-100.00%
0.37
+192.04%
-0.40
-228.03%
0.31
Special Income Charges
0.00
-100.00%
0.37
+192.04%
-0.40
-228.03%
0.31
Other Special Charges
—
-0.37
-192.04%
0.40
+228.03%
-0.31
Net Income
-32.15
-7.62%
-29.87
-5.56%
-28.30
-443.44%
-5.21
Pretax Income
-32.15
-7.62%
-29.87
-5.56%
-28.30
-588.99%
-4.11
Net Non Operating Interest Income Expense
1.07
-26.63%
1.46
+139.06%
-3.73
-164.91%
-1.41
Interest Expense Non Operating
—
0.00
-100.00%
0.82
-41.62%
1.41
Net Interest Income
1.07
-26.63%
1.46
+139.06%
-3.73
-164.91%
-1.41
Interest Expense
—
0.00
-100.00%
0.82
-41.62%
1.41
Interest Income Non Operating
1.07
-26.63%
1.46
+497.13%
0.24
0.00
Interest Income
1.07
-26.63%
1.46
+497.13%
0.24
0.00
Other Income Expense
—
0.37
+192.04%
-0.40
-228.03%
0.31
Tax Provision
—
—
0.00
-100.00%
1.10
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
-100.00%
0.07
Net Income Including Noncontrolling Interests
-32.15
-7.62%
-29.87
-5.56%
-28.30
-443.44%
-5.21
Net Income From Continuing Operation Net Minority Interest
-32.15
-7.62%
-29.87
-5.56%
-28.30
-443.44%
-5.21
Net Income From Continuing And Discontinued Operation
-32.15
-7.62%
-29.87
-5.56%
-28.30
-443.44%
-5.21
Net Income Continuous Operations
-32.15
-7.62%
-29.87
-5.56%
-28.30
-443.44%
-5.21
Normalized Income
-32.15
-6.30%
-30.24
-8.40%
-27.89
-411.36%
-5.46
Net Income Common Stockholders
-32.15
-7.62%
-29.87
-5.56%
-28.30
-443.44%
-5.21
Diluted EPS
-0.86
+9.47%
-0.95
+18.10%
-1.16
-425.08%
-0.22
Basic EPS
-0.86
+9.47%
-0.95
+18.10%
-1.16
-425.08%
-0.22
Basic Average Shares
37.18
+18.21%
31.45
+28.74%
24.43
+3.31%
23.65
Diluted Average Shares
37.18
+18.21%
31.45
+28.74%
24.43
+3.31%
23.65
Diluted NI Availto Com Stockholders
-32.15
-7.62%
-29.87
-5.56%
-28.30
-443.44%
-5.21
Insurance And Claims
0.87
-9.94%
0.97
-10.39%
1.08
+222.75%
0.33
Total Other Finance Cost
—
—
3.15
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
19.03
-45.19%
34.72
+24.46%
27.89
Current Assets
15.13
-52.04%
31.55
+30.35%
24.20
Cash Cash Equivalents And Short Term Investments
14.60
-52.76%
30.89
+33.22%
23.19
Cash And Cash Equivalents
5.33
-37.73%
8.56
-9.06%
9.42
Cash Equivalents
—
7.58
-4.37%
7.92
Cash Financial
—
0.99
-33.94%
1.49
Other Short Term Investments
9.26
-58.52%
22.33
+62.13%
13.77
Prepaid Assets
—
—
—
Other Current Assets
0.54
-18.07%
0.65
-35.47%
1.01
Total Non Current Assets
3.90
+23.01%
3.17
-14.15%
3.69
Net PPE
3.75
+22.01%
3.08
-14.51%
3.60
Gross PPE
7.68
+13.61%
6.76
-4.07%
7.05
Accumulated Depreciation
-3.93
-6.60%
-3.68
-6.81%
-3.45
Properties
0.00
0.00
0.00
Machinery Furniture Equipment
0.28
+0.00%
0.28
+0.00%
0.28
Construction In Progress
2.35
+80.68%
1.30
+30.55%
0.99
Other Properties
4.50
-2.77%
4.63
-11.32%
5.22
Leases
0.56
+0.00%
0.56
+0.00%
0.56
Non Current Deferred Assets
—
—
0.00
Other Non Current Assets
0.14
+56.52%
0.09
+0.00%
0.09
Total Liabilities Net Minority Interest
7.48
-11.36%
8.44
+0.26%
8.42
Current Liabilities
6.22
-9.82%
6.90
+5.32%
6.55
Payables And Accrued Expenses
4.36
-21.76%
5.57
+47.20%
3.78
Payables
4.36
-21.76%
5.57
+47.20%
3.78
Accounts Payable
4.36
-21.76%
5.57
+47.20%
3.78
Current Accrued Expenses
1.44
+43.43%
1.00
-52.57%
2.12
Pensionand Other Post Retirement Benefit Plans Current
1.44
+43.43%
1.00
-52.57%
2.12
Current Debt And Capital Lease Obligation
0.43
+29.79%
0.33
-49.62%
0.65
Current Debt
—
—
—
Other Current Borrowings
—
—
—
Current Capital Lease Obligation
0.43
+29.79%
0.33
-49.62%
0.65
Current Deferred Liabilities
—
—
0.00
Current Deferred Revenue
—
—
0.00
Other Current Liabilities
—
—
—
Total Non Current Liabilities Net Minority Interest
1.26
-18.26%
1.54
-17.52%
1.87
Long Term Debt And Capital Lease Obligation
1.26
-18.26%
1.54
-17.52%
1.87
Long Term Debt
—
—
—
Long Term Capital Lease Obligation
1.26
-18.26%
1.54
-17.52%
1.87
Stockholders Equity
11.54
-56.06%
26.27
+34.93%
19.47
Common Stock Equity
11.54
-56.06%
26.27
+34.93%
19.47
Capital Stock
0.04
+8.57%
0.04
+29.63%
0.03
Common Stock
0.04
+8.57%
0.04
+29.63%
0.03
Preferred Stock
—
0.00
0.00
Share Issued
38.57
+9.70%
35.16
+29.16%
27.22
Ordinary Shares Number
38.14
+9.82%
34.73
+29.64%
26.79
Treasury Shares Number
0.43
+0.00%
0.43
+0.00%
0.43
Additional Paid In Capital
295.47
+6.28%
278.00
+15.17%
241.39
Retained Earnings
-283.54
-12.79%
-251.39
-13.48%
-221.52
Gains Losses Not Affecting Retained Earnings
0.01
-85.94%
0.06
+357.14%
0.01
Treasury Stock
0.43
+0.00%
0.43
+0.00%
0.43
Other Equity Adjustments
0.01
-85.94%
0.06
+357.14%
0.01
Total Equity Gross Minority Interest
11.54
-56.06%
26.27
+34.93%
19.47
Total Capitalization
11.54
-56.06%
26.27
+34.93%
19.47
Working Capital
8.90
-63.87%
24.64
+39.64%
17.65
Invested Capital
11.54
-56.06%
26.27
+34.93%
19.47
Total Debt
1.69
-9.80%
1.87
-25.84%
2.52
Net Debt
—
—
—
Capital Lease Obligations
1.69
-9.80%
1.87
-25.84%
2.52
Net Tangible Assets
11.54
-56.06%
26.27
+34.93%
19.47
Tangible Book Value
11.54
-56.06%
26.27
+34.93%
19.47
Current Notes Payable
—
—
0.00
Interest Payable
—
—
0.00
Preferred Stock Equity
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-25.27
-19.03%
-21.23
-4.70%
-20.27
-467.77%
-3.57
Cash Flow From Continuing Operating Activities
-25.27
-19.03%
-21.23
-4.70%
-20.27
-467.77%
-3.57
Net Income From Continuing Operations
-32.15
-7.62%
-29.87
-5.56%
-28.30
-443.44%
-5.21
Depreciation Amortization Depletion
0.57
-36.43%
0.90
-11.30%
1.02
+5.17%
0.97
Depreciation
0.57
-36.43%
0.90
-11.30%
1.02
+5.17%
0.97
Depreciation And Amortization
0.57
-36.43%
0.90
-11.30%
1.02
+5.17%
0.97
Other Non Cash Items
0.90
-46.36%
1.67
+5.35%
1.59
+2937.50%
-0.06
Stock Based Compensation
6.68
+10.00%
6.07
+16.64%
5.20
+115.49%
2.42
Operating Gains Losses
—
—
3.55
—
Gain Loss On Investment Securities
—
—
3.15
—
Change In Working Capital
-1.05
-239.28%
0.75
+122.89%
-3.28
-94.03%
-1.69
Change In Prepaid Assets
0.07
-81.62%
0.36
-25.67%
0.48
+387.50%
-0.17
Change In Payables And Accrued Expense
-0.78
-174.30%
1.04
+133.96%
-3.07
-196.09%
3.20
Change In Accrued Expense
0.44
+139.35%
-1.11
-56.10%
-0.71
-180.75%
0.88
Change In Payable
-1.21
-156.26%
2.16
+191.43%
-2.36
-201.95%
2.31
Change In Account Payable
-1.21
-156.26%
2.16
+191.43%
-2.36
-201.95%
2.31
Change In Other Working Capital
—
—
-0.17
+96.07%
-4.33
Change In Other Current Liabilities
-0.34
+48.23%
-0.65
-24.47%
-0.52
-34.45%
-0.39
Investing Cash Flow
12.14
+249.32%
-8.13
+44.78%
-14.72
-29948.98%
-0.05
Cash Flow From Continuing Investing Activities
12.14
+249.32%
-8.13
+44.78%
-14.72
-29948.98%
-0.05
Net PPE Purchase And Sale
-1.10
-188.19%
-0.38
+62.83%
-1.02
-1991.84%
-0.05
Purchase Of PPE
-1.10
-188.19%
-0.38
+62.83%
-1.02
-1991.84%
-0.05
Capital Expenditure
-1.10
-188.19%
-0.38
+62.83%
-1.02
-1991.84%
-0.05
Net Investment Purchase And Sale
13.24
+270.83%
-7.75
+43.43%
-13.70
0.00
Purchase Of Investment
-18.26
+37.03%
-29.00
-111.69%
-13.70
0.00
Sale Of Investment
31.50
+48.24%
21.25
0.00
—
Financing Cash Flow
9.89
-65.29%
28.51
-35.24%
44.02
+9309.21%
-0.48
Cash Flow From Continuing Financing Activities
9.89
-65.29%
28.51
-35.24%
44.02
+9309.21%
-0.48
Net Issuance Payments Of Debt
—
0.00
-100.00%
0.21
-77.84%
0.97
Issuance Of Debt
—
0.00
-100.00%
0.90
-18.18%
1.10
Repayment Of Debt
—
0.00
+100.00%
-0.69
-426.92%
-0.13
Long Term Debt Issuance
—
—
—
1.10
Long Term Debt Payments
—
—
0.00
+100.00%
-0.13
Net Long Term Debt Issuance
—
—
0.00
+100.00%
-0.13
Short Term Debt Issuance
—
0.00
-100.00%
0.90
-18.18%
1.10
Short Term Debt Payments
—
0.00
+100.00%
-0.69
0.00
Net Short Term Debt Issuance
—
0.00
-100.00%
0.21
-80.45%
1.10
Net Common Stock Issuance
9.66
-65.29%
27.82
-29.83%
39.65
0.00
Proceeds From Stock Option Exercised
0.24
-65.41%
0.69
-84.58%
4.46
+3619.17%
0.12
Net Other Financing Charges
—
—
-0.30
+80.68%
-1.57
Changes In Cash
-3.23
-278.90%
-0.85
-109.46%
9.02
+320.13%
-4.10
Beginning Cash Position
8.56
-9.06%
9.42
+2272.29%
0.40
-91.17%
4.50
End Cash Position
5.33
-37.73%
8.56
-9.06%
9.42
+2272.29%
0.40
Free Cash Flow
-26.37
-22.01%
-21.61
-1.45%
-21.30
-488.40%
-3.62
Interest Paid Supplemental Data
—
0.00
-100.00%
0.07
-72.73%
0.26
Income Tax Paid Supplemental Data
—
0.00
0.00
0.00
Amortization Of Securities
-0.23
+70.15%
-0.76
-1120.97%
-0.06
0.00
Change In Interest Payable
—
0.00
-100.00%
0.02
-97.52%
0.89
Common Stock Issuance
9.66
-65.29%
27.82
-29.83%
39.65
0.00
Issuance Of Capital Stock
9.66
-65.29%
27.82
-29.83%
39.65
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category